TET2 exon 2 skipping is an independent favorable prognostic factor for cytogenetically normal acute myelogenous leukemia (AML): TET2 exon 2 skipping in AML
A. M Mohamed, M. Balsat, C. Koering, D. Maucort-Boulch, N. Boissel, L. Payen-Gay, M. Cheok, H. Mortada, D. Auboeuf, C. Pinatel, M. El-Hamri, I. Tigaud, S. Hayette, C. Dumontet, E. Cros, P. Flandrin-Gresta, O. Nibourel, C. Preudhomme, X. Thomas, F. E Nicolini, F. Solly, D. Guyotat, L. Campos, M. Michallet, A. Ceraulo, F. Mortreux, and E. Wattel
(2017)
Leuk Res, 56:21–28.
Directory
